Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
View in:
PubMed
subject areas
Anemia
Chronic Disease
Consumer Product Safety
Drug Labeling
Evidence-Based Medicine
Hematinics
Hemoglobins
Humans
Kidney Diseases
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Treatment Outcome
United States
United States Food and Drug Administration
Up-Regulation
authors with profiles
Ajaypal Singh